Navigation Links
Vaxart Begins First Oral Vaccine Clinical Trial
Date:6/7/2011

SAN FRANCISCO, June 7, 2011 /PRNewswire/ -- Vaxart, Inc., a San Francisco biotechnology company developing oral-delivery vaccines, has begun dosing volunteers in a Phase I clinical trial. This is the first clinical study evaluating a vaccine that uses the company's novel oral-vaccine platform technology. The trial site is in the United States.

"This first trial in humans is important, because if safety is demonstrated with one vaccine, we can expect that later vaccines using the same Vaxart technology will also be safe," said Vaxart founder and CSO Sean Tucker, Ph.D.

Vaxart's first oral vaccine candidate is designed to protect against H5N1 Avian Influenza. The company also has a pipeline of additional vaccines in development, all based on its oral-delivery technology.

Vaxart also announced the issuance of U.S. patent no. 7,879,602, which provides broad protection for the company's oral-delivery technology. "This patent greatly increases the value of our portfolio because it covers all methods we know of for oral vaccination with a re-usable platform technology," said Vaxart CEO Michael Finney, Ph.D.

About Vaxart TechnologyVaxart leverages proprietary vaccine development and formulation approaches to quickly and efficiently produce oral-delivery vaccines. Central to the company's approach is the incorporation of a unique adjuvant, the vaccine component that enhances immune responses, in the vector that delivers the vaccine antigen. Vaxart's adjuvant works by binding to Toll-Like Receptor 3 to stimulate a potent immune response when the vaccine is taken orally.

Vaxart's technology also enables all of the company's vaccines to use the same vector, or delivery vehicle. Until now, each time an individual received a vector vaccine, a new vector needed to be used. This is because after receiving a vector vaccine, people develop antibodies to the vector itself, and these anti-vector antibodies reduce the effectiveness of later vaccin
'/>"/>

SOURCE Vaxart, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies
2. Vaxart Begins Animal Testing of H1N1 Flu Vaccine Candidate
3. GSK Begins Shipments of Fluarix(R) and FluLaval(R) to U.S. Customers for 2008-2009 Influenza Season
4. Cellectar, Inc. Begins GMP Production
5. South Africa Begins Introduction of PREVENAR into Childhood Immunization Program
6. Major Adult Vaccine Clinical Trial for Pneumonia Prevention Begins
7. The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline
8. Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline
9. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
10. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
11. SemBioSys begins phase I/II trial of insulin produced in plant seeds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... MILWAUKEE , Sept. 1, 2015 ... Eric Floyd , Ph.D., MBA as Chief ... (DLSS).  In this newly created role, Dr. Floyd ... well as a portfolio of pre-commercial and post ... medical affairs and medical communications.  Dr. Floyd brings ...
(Date:9/1/2015)... ... September 01, 2015 , ... Industry leader iLab Solutions recently ... this newly-created position, Gibbs will lead iLab’s business operations in the region, with ... This entails not only introducing iLab to potential partners but support and management ...
(Date:9/1/2015)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... Board of Directors as a Non-Executive Director. Sara will also ... of the Shire Board. Both appointments will be effective as ... Chairman, President and Chief Executive Officer of Dun & Bradstreet, ... at D&B, she helped drive the transformation of the company ...
(Date:8/31/2015)... DIEGO , Aug. 31, 2015 MabVax ... development company announces that the Company,s lead antibody, HuMab ... of five separate presentations during the upcoming World Molecular ... September 2-5, 2015. Researchers from the Department ... will present results on the use of MabVax,s lead ...
Breaking Biology Technology:Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 2Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 3iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 2iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 3Shire Appoints Sara Mathew to Board of Directors 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4
... 6, 2011 Van Andel Education Institute (VAEI) has ... to cooperatively recruit students interested in research training in ... genetic biology of human disease.    Under ... will work together to recruit qualified students at historically ...
...  Research Corporation for Science Advancement ( www.rescorp.org ), ... wholly to science, and the second-oldest overall (after ... its Honorary Centennial Observance Committee. The Committee, which ... 2012, is comprised of some of the most ...
... Inc. (Nasdaq: ECTE ), a company developing ... continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep ... from its clinical study of its Symphony tCGM System ... Data from the study confirm that Symphony successfully monitors ...
Cached Biology Technology:Van Andel Institute Partners with UNCF to Recruit Students to Biomedical Research Careers 2Leaders in Science Join Upcoming Celebration of the 100th Anniversary of the Oldest Science Foundation in America 2Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes 2Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes 3Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes 4
(Date:8/25/2015)... LAKE CITY and BELLEVUE, Wash. ... global leader in advanced robotic systems, announced today it ... robotic unmanned ground vehicle (UGV), at the National Tactical ... City.  The Guardian S is the ... the culmination of years of research and in-field trials ...
(Date:8/20/2015)... ., Aug. 20, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... it has joined The Smart Card Alliance and the ... Card Alliance and the Smart Card Alliance Latin America ... to industry peers and thought leaders promoting adoption of ...
(Date:8/12/2015)... 12, 2015   MedNet Solutions , an innovative ... of clinical research, is proud to announce that ... SaaS-based eClinical technology platform, has led the way to ... quarters of 2015.   Q2 2015 and Q1 2015 ... by contract value sold in the company,s 15 year ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2
... diverse potential applications include the development of ... coatings for medical implants, coatings for semiconductors, ... materials, microelectronics and responsive nanomaterials, and surface-sensitive ... The patented technology stems from the discovery ...
... have contended for millennia that burning incense is good ... is good for our brains too. In a new ... ), an international team of scientists, including researchers from ... describe how burning frankincense (resin from the Boswellia plant) ...
... First identified in 1899, y-larvae have been one of ... one has ever found an adult of these puzzling ... leading generations of marine zoologists to wonder just what ... in BioMed Centrals open access journal, BMC Biology, reports ...
Cached Biology News:Scripps Research Institute awarded patent for remarkable chemical technology 2Scripps Research Institute awarded patent for remarkable chemical technology 3Scripps Research Institute awarded patent for remarkable chemical technology 4Incense is psychoactive: Scientists identify the biology behind the ceremony 2Clue to mystery crustacean in parasite form 2
... Specificity: This antibody recognizes murine ... cross-react with other related IRF ... with murine IRF7 protein was ... of the 293T cells transfected ...
... PS603. Immunogen: Synthetic phosphopeptide ... the phosphorylated Ser603 residue of ... Specific for synapsin I when ... Reactivity: Rat (positive control: ...
MMP-20 Immunogen: Activated recombinant human MMP-2 Storage: -20 C, Avoid Freeze/Thaw Cycles...
karyopherin alpha2 (2G7)...
Biology Products: